Artificial Intelligence in Diabetes Management Global Market Report 2024

The artificial intelligence in diabetes management market size has grown exponentially in recent years. It will grow from $0.48 billion in 2023 to $0.63 billion in 2024 at a compound annual growth rate (CAGR) of 31.6%. The growth observed in the historical period can be attributed to the accumulation of data, the increasing prevalence of diabetes cases, pressures on healthcare costs, and the early applications of artificial intelligence in diabetes management.

The artificial intelligence in diabetes management market size is expected to see exponential growth in the next few years. It will grow to $1.89 billion in 2028 at a compound annual growth rate (CAGR) of 31.7%. The anticipated growth in the forecast period can be attributed to the implementation of AI-powered decision support systems, integration with telemedicine, utilization of genomic data, and regulatory support for artificial intelligence in diabetes management. Key trends expected during this period encompass advancements in wearable technology, the development of personalized treatment plans, continuous glucose monitoring advances, AI-powered risk prediction, and support for behavioral modification.

The anticipated surge in diabetes cases is set to drive the adoption of artificial intelligence within the diabetes management market. Diabetes, characterized by elevated blood glucose levels, leads to various complications such as eye issues, cardiovascular problems such as heart attacks and strokes, kidney ailments, among others. Artificial intelligence plays a pivotal role in diabetes management by furnishing insights into diabetic patients' fluctuating blood sugar levels and harnessing previously untapped data. For instance, in December 2021, as reported by the International Diabetes Federation, an intergovernmental organization in the US, the global diabetic population among adults (20–79 years old) stood at 537 million and is forecasted to escalate to 643 million by 2030 and 783 million by 2045. Thus, the mounting prevalence of diabetes is fueling the integration of artificial intelligence in diabetes management practices.

The escalating demand for telehealth services is poised to bolster the adoption of artificial intelligence within the diabetes management domain. Telehealth involves leveraging telecommunications and digital tools to deliver remote healthcare services to patients and healthcare providers. The amalgamation of artificial intelligence into diabetes care within telehealth services amplifies personalization, monitoring capabilities, and overall efficiency. This integration aids in early complication detection, promotes medication adherence, and provides enhanced decision-making support, thereby elevating patient outcomes and optimizing healthcare resources. For instance, in April 2023, FAIR Health Inc., a non-profit organization in the US, reported a 7.3% surge in national telehealth usage, rising from 5.5% of medical claim lines in December 2022 to 5.9% in January 2023. Consequently, the escalating demand for telehealth services is propelling the advancement of artificial intelligence in the realm of diabetes management.

Advancements in technology stand out as a prominent trend gaining traction within the artificial intelligence segment of the diabetes management market. Key players in this domain are dedicated to pioneering cutting-edge technological solutions to fortify their market presence. For instance, in October 2022, Dr. Mohan’s Diabetes Specialties Center, an India-based chain of hospitals specializing in diabetes care, introduced a groundbreaking artificial intelligence-driven platform for precision diabetes care known as the 3D Initiative. The initiative comprises three components such as DIA, an AI-powered chatbot facilitating pre-recorded digital interactions; DIALA, a user-friendly smartphone application tailored for patients; and DIANA, a medical app focusing on precise diabetic care. Backed by an advanced Total Experience (TX) Automation Platform, this innovation powers an AI-enabled virtual assistant engaging with patients across platforms such as Facebook Messenger, WhatsApp, Google Business Message, and the web.

Significant players in the artificial intelligence sphere of diabetes management are actively developing novel products such as wearable devices aimed at monitoring glucose levels to gain a competitive edge in the market. Wearable glucose monitoring devices are compact, often technologically advanced gadgets designed to continuously or intermittently measure and monitor blood glucose levels. For instance, in October 2023, Dexcom Inc., a US-based medical device manufacturing company, introduced the next-generation G7 continuous glucose monitoring (CGM) system. This system caters to all diabetics nationwide, including pregnant individuals and those aged two years or older. The Dexcom CGM device ensures enhanced user safety by providing alerts for severe hypoglycemia up to 20 minutes in advance, thereby reducing uncertainty in diabetes management. Moreover, the system simplifies sensor replacement with a 12-hour grace period, and its remote monitoring feature facilitates the exchange of glucose data with up to 10 followers.

In January 2022, Glooko Inc., a leading US-based digital diabetes and chronic condition management company, successfully acquired Xbird for an undisclosed amount. Through this acquisition, Xbird is set to play a crucial role in Glooko's strategic vision for leveraging artificial intelligence and providing tailored digital coaching for individuals dealing with chronic diseases. The integration of xbird's innovative Just in Time Adaptive Intervention (JITAI) capabilities with Glooko's well-established global presence is expected to enhance patient outcomes. Xbird GmbH, the acquired company, is based in Germany and specializes in AI-enabled diabetes management.

Major companies operating in the artificial intelligence in diabetes management market report are Alphabet Inc., F. Hoffmann-La Roche AG, Abbott Laboratories, Medtronic Plc, Dexcom Inc., Insulet Corporation, Tandem Diabetes Care Inc., LifePlus Inc., Livongo Health Inc., Xeris Pharmaceuticals Inc., Virta Health Corp., Informed Data Systems Inc., Bigfoot Biomedical Inc., Lark Technologies Inc., Smart Meter LLC, Diabeloop SA, Quin Technology Ltd., Wellthy Therapeutics Pvt Ltd., Admetsys LLC, DreaMed Diabetes Ltd., Eyenuk Inc., Glooko Inc., PKvitality, Glytec LLC, Hygieia Inc., TypeZero Technologies Inc., Nemaura Medical Inc., GlucoMe, PredictBGL, Voluntis S.A.

North America was the largest region in the artificial intelligence (AI) in diabetes management market in 2023. The regions covered in the artificial intelligence in diabetes management market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence in diabetes management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The primary devices integrated into artificial intelligence in diabetes management include diagnostic devices, glucose monitoring devices, insulin delivery devices, and others. Diagnostic devices play a crucial role in determining the nature or underlying cause of specific phenomena, particularly those associated with health issues such as diabetes. The various techniques employed in this context include case-based reasoning and intelligent data analysis. These technologies find application in diverse settings, including hospitals, clinics, home care settings, and research institutes.

The artificial intelligence in diabetes management market research report is one of a series of new reports that provides artificial intelligence in diabetes management market statistics, including the artificial intelligence in diabetes management industry's global market size, regional shares, competitors with artificial intelligence in diabetes management market share, detailed artificial intelligence in diabetes management market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence in diabetes management industry. This artificial intelligence in diabetes management market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The artificial intelligence in diabetes management market consists of revenues earned by entities by providing automated retinal screening, clinical decision support, disease prediction, and treatment management. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence in the diabetes management market also includes sales of glucose monitors, support vector machines, and smart wearables. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.